GMP-grade mRNA Synthesis and Capping enzymes
Messenger RNA vaccines against COVID-19 are widely used ever since the pandemic outbreak due to their safety, rapid development, and potent immunogenicity. The mRNA molecules designed to encode virus antigens are synthesized with phage RNA polymerases and then 5' modified with capping enzymes. YEASEN, a biotech company focused on enzyme development and production, offers GMP-grade enzymes used during the RNA synthesis and 5’-capping steps. These products are manufactured and inventoried at GMP-grade and are suitable for various applications, including vaccine production and therapeutic products manufacturing.
1. RNA synthesis — UCF·METM T7 RNA Polymerase (GMP-grade)
UCF·METM T7 RNA Polymerase (GMP-grade) is a recombinant enzyme obtained from Escherichia coli, which catalyzes in vitro RNA synthesis from NTP on DNA template downstream T7 promoters (5'-TAATACGACT CACTATAG*-3'). This T7 RNA Polymerase enables the synthesis of both short (<200nt) and long (500nt-4000nt) RNA transcripts with high promoter-specificity and high RNA yield.
Overall higher yields of RNA were synthesized using the UCF·METM T7 RNA Polymerase compared to a competitor's product. Efficient mRNA synthesis observed for templates of various sizes, with high RNA integrity and high promoter-specificity
2. Cap-0 Modification — UCF·METM mRNA Vaccinia Capping Enzyme (GMP-grade)
5' cap is required for the stabilization, transport, and translation of mRNA. YEASEN's GMP-grade UCF.METM mRNA Vaccinia Capping Enzyme is a multi-functional mRNA-capping enzyme composed of two subunits (D1 and D12), exhibiting RNA 5’-triphosphatase activity, guanylyltransferase activity, and guanine methyltransferase activity. The enzyme enables the addition of 7-methylguanylate Cap-0 structure (m7Gppp) to the 5' end of RNA. Under proper conditions and with materials like reaction buffer, GTP and SAM, the capping enzyme can finish RNA capping within one hour, with the correct orientation, and with an efficiency of nearly 100%.
3. Cap-1 Modification —UCF·METM mRNA Cap 2´-O-Methyltransferase (GMP-grade)
The Cap-1 structure enhances the translation efficiency and reduces the immunogenicity of the mRNA. YEASEN's GMP-grade UCF·METM mRNA Cap 2´-O-Methyltransferase is a recombinant protein obtained from an E. Coli strain that expresses the gene for the Vaccinia mRNA Cap 2’-O-Methyltransferase. The enzyme adds a methyl group at the 2’-O position of the first nucleotide adjacent to the mRNA's Cap-0 structure to form a Cap-1 structure. It requires SAM as the methyl donor and RNA with m7Gppp cap as the substrate.
Our featured products related to COVID-19 mRNA Vaccine Manufacturing
Yeasen has a production capacity of up to 800L per batch of fermentation. All our production processes are performed under stringent quality controls to eliminate batch-to-batch variation. With our adequate inventory, we can continuously provide you the products you need at reasonable prices! Contact us to learn more about our products and to get free samples to test out! (Please kindly note that YEASEN will not cover the shipping fees.)
Biotechnology (Shanghai) Co., Ltd. was founded in 2014 and
Headquartered in Shanghai International Medical Zone. With our continued
dedication to developing and producing high-quality enzyme products, we
have become one of China’s top brands in molecular biology enzyme
manufacturing. We are able to offer a broad selection of enzymes and
reagents for research and applications such as molecular and cell
biology studies, next-generation sequencing (NGS), and in vitro
diagnostics (IVD). As
a biotech company with a mission of contributing to the advancement of
life sciences, YEASEN took quick actions to develop and produce products
to help in this fight against Coronavirus. We are incredibly honored to
make an impact in this battle and will continually provide high-quality
products to assist the research, diagnostics, vaccination, and
treatment of Coronavirus.